These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32379167)

  • 1. RETAINED, NONDISSOLVING, TUBULAR FOREIGN BODIES IN THE VITREOUS CAVITY AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANTATION.
    Han IC; Critser DB; Amram AL; Folk JC
    Retina; 2020 Nov; 40(11):2221-2225. PubMed ID: 32379167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX).
    Kim JT; Lee SH; Choi SU
    Retina; 2020 Nov; 40(11):2226-2231. PubMed ID: 32058420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report.
    Pacella F; Agostinelli E; Carlesimo SC; Nebbioso M; Secondi R; Forastiere M; Pacella E
    J Med Case Rep; 2016 Oct; 10(1):282. PubMed ID: 27733187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning and follow-up of intralenticular dexamethasone implant.
    Munteanu M; Rosca C
    J Cataract Refract Surg; 2013 Aug; 39(8):1271-4. PubMed ID: 23889870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex).
    Ong J; Davidoss NH; Bhosale A; Balaratnasingam C
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Anterior Chamber Migration of Dexamethasone Intravitreal Implant.
    Ha JY; Jang JY; Ji YS
    Korean J Ophthalmol; 2017 Dec; 31(6):574-575. PubMed ID: 29230981
    [No Abstract]   [Full Text] [Related]  

  • 7. Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony.
    Kong X; Psaras C; Stewart JM
    Ophthalmol Retina; 2019 Nov; 3(11):993-997. PubMed ID: 31371197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Adjunctive Sustained-Release Intravitreal Dexamethasone Implants in Tuberculosis-Associated Multifocal Serpigenoid Choroiditis.
    Jain L; Panda KG; Basu S
    Ocul Immunol Inflamm; 2018; 26(6):877-883. PubMed ID: 29020496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
    Arcinue CA; Cerón OM; Foster CS
    J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis.
    Palla S; Biswas J; Nagesha CK
    Indian J Ophthalmol; 2015 Oct; 63(10):767-70. PubMed ID: 26655000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis.
    Bratton ML; He YG; Weakley DR
    J AAPOS; 2014 Apr; 18(2):110-3. PubMed ID: 24698604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis.
    Kim M; Kim SA; Park W; Kim RY; Park YH
    Adv Ther; 2019 Aug; 36(8):2137-2146. PubMed ID: 31140122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis.
    Sella R; Oray M; Friling R; Umar L; Tugal-Tutkun I; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1777-82. PubMed ID: 26228441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema.
    Scaramuzzi M; Querques G; Spina CL; Lattanzio R; Bandello F
    Retina; 2015 Jun; 35(6):1216-22. PubMed ID: 25574787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome.
    Dutra Medeiros M; Navarro R; Garcia-Arumí J; Mateo C; Corcóstegui B
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3320-4. PubMed ID: 23599334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration.
    Röck D; Bartz-Schmidt KU; Röck T
    BMC Ophthalmol; 2019 May; 19(1):120. PubMed ID: 31138164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suspected bacterial endophthalmitis following sustained-release dexamethasone intravitreal implant: a case report.
    Arıkan Yorgun M; Mutlu M; Toklu Y; Cakmak HB; Cağıl N
    Korean J Ophthalmol; 2014 Jun; 28(3):275-7. PubMed ID: 24882964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone intravitreal implant (OZURDEX
    Massa H; Georgoudis P; Panos GD
    Ther Deliv; 2019 Jun; 10(6):343-351. PubMed ID: 31184554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa.
    Srour M; Querques G; Leveziel N; Zerbib J; Tilleul J; Boulanger-Scemama E; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1501-6. PubMed ID: 23275039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
    Bakri SJ; Omar AF
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.